The Latest Cardiac and Vascular News
– Second quarter Orenitram® revenue growth of 40% year-over-year – INCREASE sNDA submitted to FDA SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 29, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2020. “I […]
– First quarter Orenitram® net revenue growth of 18% year-over-year – Major milestones such as the INCREASE filing and Remunity™ Pump launch remain on track despite the COVID-19 pandemic – United Therapeutics is engaged in the fight against COVID-19 SILVER […]
– Orenitram demonstrated improvement in hemodynamic parameters and risk status, important indicators of long-term outcomes in PAH patients, in presentations at recent scientific conferences – Separately, total PAH-related patient healthcare costs are 67% higher for selexipag in article published in […]
